胆囊良恶性病变癌干细胞标记蛋白表达及转移侵袭调控机制研究
摘要
第一部分癌干细胞及其标记物研究
目的研究胆囊腺癌、癌旁上皮、腺瘤性息肉和慢性胆囊炎组织中前列腺干细胞抗原(prostate stem cell antigen,PSCA)、Oct-4干细胞抗原(Oct-4)、CD24和CD_(44V)6表达水平,探讨其临床病理意义及在胆囊腺癌发生发展中的作用及作用机理。
方法108例胆囊腺癌、46例癌旁组织、15例腺瘤性息肉和35例慢性胆囊炎手术切除标本经4%甲醛固定后常规制作石蜡包埋切片,PSCA、Oct-4、CD24和CD_(44V)6染色方法均为Envision~(TM)免疫组化二步法。
结果(1)108例胆囊腺癌PSCA、Oct-4、CD24和CD_(44V)6表达阳性病例分别为59例(54.6%)、60例(55.6%)、57例(52.8%)和60例(55.6%),其评分值分别为2.09±1.94、2.06±1.86,2.43±1.65和2.52±1.60;46例癌旁组织PSCA、Oct-4、CD24和CD_(44V)6表达阳性病例分别为9例(19.6%)、10例(22.5%)、8例(17.4%)和9例(19.6%),其评分值分别为0.82±1.11、0.85±1.02、0.78±1.36和0.82±1.39;15例腺瘤性息肉PSCA、Oct-4、CD24和CD_(44V)6表达阳性病例分别为4例(26.7%)、3例(20.0%)、3例(20.0%)和4例(26.7%),其评分值分别为0.74±1.25、0.69±1.32、0.72±1.35和0.78±1.28;35例慢性胆囊炎PSCA、Oct-4、CD24和CD_(44V)6表达阳性病例分别为5例(14.3%)、5例(14.3%)、4例(11.4%)和6例(17.1%),其评分值分别为0.68±1.21、0.67±0.95、0.54±1.44和0.58±1.46;PSCA、Oct-4、CD24或(和)CD_(44V)6表达阳性的癌旁组织、腺瘤性息肉和慢性胆囊炎胆囊上皮均呈中度至重度不典型增生;胆囊腺癌PSCA、Oct-4、CD24和CD_(44V)6表达阳性率及其评分明显高于癌旁上皮(PSCA,x~2=10.09,P<0.01,τ=4.23,P.x~2<0.01 Oct-4,x~2=14.88,P<0.01,τ=4.32,P<0.01;CD24,x~2=16.58,P<0.01,τ=5.89,P<0.01;CD_(44V)6,x~2=16.90,P<0.01,τ=6.07,P<0.01)、腺瘤性息肉(PSCA,x~2=4.12,P<0.05,τ=2.60,P<0.05;Oct-4,x~2=6.66,P<0.01,τ=280,P<0.01;CD24,x~2=5.66,P<0.05,τ=3.78 P<0.01;CD_(44V)6,X~2=4.12,P<0.05,τ=4.05,P<0.01)和慢性胆囊炎(PSCA,X~2=17.40,P<0.01,τ=4.15,P<0.01;Oct-4,x~2=18.16,P<0.01,τ=4.21,P<0.01;CD24,x~2=18.48,P<0.01,τ=6.10,P<0.01;CD_(44V)6,x~2=15.69,τ=6.26,P(0.01)。
(2)腺瘤癌变或高分化腺癌、肿块最大径<2cm、无淋巴结转移及侵犯胆囊外周围组织器官病例PSCA、Oct-4、CD24和CD_(44V)6表达阳性率及其评分明显低于低分化腺癌、肿块最大径≥2cm、淋巴结转移及侵犯胆囊外周围组织器官病例,差异均有显著性或高度显著性(P<0.05或P<0.01)。
(3)胆囊腺癌中PSCA、Oct-4、CD24和CD_(44V)6表达水平相互之间具有高度一致性(P<0.01),其评分值相互之间存在密切正相关(PSCAvs Oct-4,r=0.44,P<0.01;PSCA vs CD24,r=0.36,P<0.01;PCSA vsCD_(44V)6,r=0.49;P<0.01,Oct-4 vs CD24,r=0.51,P<0.01;Oct-4 vsCD_(44V)6,r=0.39,P<0.01;CD24 vs CD_(44V)6,r=0.48,P<0.01)。
结论PSCA、Oct-4、CD24和CD_(44V)6作为癌干细胞标记物在胆囊腺癌发生、进展、转移及侵袭潜力方面具有重要作用,阳性或高水平表达者临床预后不良;癌组织中存在的癌干细胞有可能在胆囊腺癌发生发展中起重要作用,且影响胆囊腺癌临床生物学行为及其预后;检测胆囊良性病变组织中PSCA、Oct-4、CD24和CD_(44V)6 4种癌干细胞标记物表达水平对预防和早期发现胆囊癌可能具有重要临床应用价值。
第二部分胆囊腺癌转移和侵袭调控机制研究
第一章胆囊良恶性病变微血管和淋巴管计数及其意义
目的研究胆囊腺癌、癌旁组织、腺瘤性息肉和慢性胆囊炎组织中微血管(MV)和淋巴管(LV)计数及其临床病理意义。
方法108例胆囊腺癌、46例癌旁组织、15例腺瘤性息肉和35例慢性胆囊炎外科手术切除标本经4%甲醛固定后常规制作石蜡包埋切片,MV和LV染色方法均为S-P免疫组化法,低倍镜下选择MV和LV分布最丰富的10个区域,高倍镜下计数10个区域内MV和LV数,取其均值为该病例计数值。
结果108例胆囊腺癌MV和LV计数均值(64.2±11.6,11.4±5.2)明显高于癌旁组织(28.2±12.4,τ=17.6,P<0.01;6.8±6.2,τ=4.63,P<0.01)、腺瘤性息肉(32.4±11.8,τ=9.94,P<0.01;5.6±2.9,τ=4.17,P<0.01)和慢性胆囊炎(22.2±11.3,τ=18.26,P<0.01;5.1±3.9,τ=6.63,P<0.01)。腺瘤癌变或高分化腺癌、肿块最大径<2cm、无淋巴结转移及未侵犯周围组织器官病例MV和LV计数均值明显低于低分化腺癌、肿块最大径≥2cm、淋巴结转移及侵犯周围组织器官病例(P<0.01)。胆囊腺癌中MV计数与LV计数呈密切正相关(r=0.38,P<0.01)。
结论MV和LV计数可能是反映胆囊腺癌进展,临床生物学行为及预后的标记物
第二章转移抑制调控基因的研究
目的研究胆囊腺癌、癌旁组织、腺瘤性息肉和慢性胆囊炎组织中KAI-1mRNA、Kiss-1mRNA、MTA1和CD146表达水平及其临床病理意义。
方法108例胆囊腺癌、46例癌旁组织、15例腺瘤性息肉和35例慢性胆囊炎组织经4%甲醛固定后常规制作石蜡包埋切片,KAL-1mRNA和Kiss-1mRNA染色方法为原位杂交染色方法,MTA1和CD146染色方法为Envision~(TM)免疫组化二步法。
结果(1)胆囊腺癌KAL-1mRNA和Kiss-1mRNA表达阳性率(51.9%,53.7%)明显地低于癌旁组织(KAL-1mRNA,80.4%,x~2=11.02,P<0.01;Kiss-1mRNA,82.6%,x~2=11.48,P<0.01)腺瘤性息肉(KAL-1mRNA,86.7%,x~2=6.48,P<0.05;Kiss-1mRNA,86.7%,x~2=5.86P<0.05)和慢性胆囊炎(KAL-1mRNA,85.7%,x~2=12.64,P<0.01;Kiss-1mRNA,85.7%,x~(22)=11.44,P<0.01);胆囊腺癌MTA1和CD146表达阳性率(48.1%,53.7%)明显高于癌旁组织(MTA1,26.1%,x~2=6.46,P<0.05;CD146,30.4%,x~2=7.02,P<0.01),腺瘤性息肉(MTA1,20.0%,x~2=4.22,P<0.05;CD146,20.0%,x~2=8.59,P<0.01)和慢性胆囊炎(MTA1,8.6%,x~2=13.31,P<0.01,CD146,5.7%,x~2=25.00,P<0.01)。
(2)腺瘤癌变或高分化腺癌、肿块最大径<2cm、无淋巴结转移及未侵犯周围组织器官病例KAL-1mRNA、Kiss-1mRNA表达阳性率明显高于低分化腺癌、肿块最大径≥2cm、淋巴结转移及侵犯周围组织器官病例(P<0.05或P<0.01),但MTA1和CD146在胆囊腺癌中表达与KAL-1mRNA、Kiss-1mRNA表达相反(P<0.05或P<0.01)。
(3)KAL-1mRNA和/或Kiss-1mRNA表达阳性胆囊腺癌MV和LV计数明显低于阴性表达病例(P<0.01);MTA1和/或CD146表达阳性胆囊腺癌MV和LV计数明显高于阴性表达病例(P<0.01)。
结论KAL-1mRNA、Kiss-1mRNA、MTA1和CD146表达水平均为反映胆囊腺癌发生、进展,临床生物学行为及预后的重要分子标记物,均为重要的调控胆囊癌等恶性肿瘤转移和侵袭能力的重要指标,其作用可能与调控肿瘤血管生成和淋巴生成有关。
Part One Cancer Stem Cells and Their Markers
Objective To study the expression levels of prostate stem cell antigen(PSCA),Oct-4,CD24 and CD44V6 in the gallbladder adenocarcinoma,perirumoral tissues,adenomatous polyp,and chronic cholecystitis,and to detect their clinicopathologic significances in gallbladder adenocarcinoma.
Methods Immunohistocemical method of EnVision~(TM)(two steps)for PSCA,Oct-4,CD24 and CD44V6 was used in the routinely paraffin-embedded sections(after 4%formaldehyde fixing)of specimens from gallbladder adenocarcinoma(n=108),peritumoral tissues(n=46), adenomatous polyp(n=15),and chronic cholecystitis(n=35)
Results(1) In the 108 cases of gallbladder adenocarcinoma,PSCA, Oct-4,CD24 and CD44V6 positive cases were respectively 59(54.6%),60 (55.6%),60(55.6),57(52.8%),and 60(55.6%),and their scores were respectively2.09±1.94,2.06±1.86,2.43±1.65,and 2.52±1.60.In the 46 cases of perirumoral tissues,PSCA,Oct-4,CD24 and CD44V6 positive cases were respectively 9(19.6%);10(22.5%);8(17.4%),and 9 (19.6%),their scores were respectively 0.82±1.11 0.85±1.02 0.78±1.36 and 0.82±1.39.In the 15 cases of adenomatous polyp,PSCA,Oct-4,CD24 and CD44V6 positive cases were respectively 4(26.7%),3(20%),and 4 (26.7%) and their scores were respectively 0.74±1.25,0.69±1.32, 0.72±1.35,and 0.78±1.28 In the 35 cases of chronic cholecystitis,PSCA,oct-4,CD24,and.CD44V6 positive cases were respectively 5(14.3%) 5(14.3%) 4(14.4%) and 6(17.1%),and their scores were respectively 0.68±1.21,0.67±0.95,0.54±1.44,and 0.58±1.46, The gallbladder epithelium of PSCA,Oct-4,CD24 and CD44V6 positive cases all showed middle to severely-atypical hyperplasia.The positive rates of PSCA,ct-4,CD24 and CD44V6 expressions and their scores in gallbladder adenocarcinoma were significantly higher than those in peritumoral tissues(PSCA,x~2=10.09,P＜0.01,τ=4.23,P＜0.01;Oct-4, x~2=14.88,P＜0.01,τ=4.32,P＜0.01;CD24,x~2=16.58,p＜0.01,t=5.89, P＜0.01;CD44V6,x~2=16.90,P＜0.01,τ=6.07,P＜0.01),adenomatous polyp (PSCA,x~2=4.12,P＜0.05;τ=2.60P＜0.05 Oct-4,x~2=6.66,p＜0.01,τ=2.80, P＜0.01;CD24,x~2=5.66,P＜0.05,τ=3.78,P＜0.01;CD44V6,x~2=4.12, P＜0.05,τ=4.05,P＜0.01),and chronic cholecystitis(PSCA,x~2=17.40, P＜0.01,τ=6.10,P＜0.01;Oct-4,x~2=18.16,p＜0.01,τ=4.21,P＜0.01;CD24, x~2=18.48,P＜0.01,τ=6.10,P＜0.01;CD44v6,x~2=15.69,P＜0.01,τ=6.62, P＜0.01).
(2)The positive rates of PSCA,Oct-4,CD24 and CD44V6 expressions and their scores were significantly lower in the cases of adenomatous canceration or well-differentiated adenocarcinoma,maximal diameter of mass＜2cm,no-metastasis of lymph node,and no-invasion of regional tissues than those in the ones of pooly-differentiated adenocarcinoma, maximal diameter of mass≥2cm,metastasis of lymph node and invasion of regional tissues(P＜0.05,or P＜0.01).
(3)Highly consistencies in PSCA,Oct-4,CD24 and CD44V6 expressions were found in gallbladder adenocarcinoma(P＜0.01),and significantly positive correlations were found among their scores(PSCA vs Oct-4,r=0.44,P＜0.01;PSCA vs CD24,r=0.36,P＜0.01;PSCA vs CD44V6,r=0.49,P＜0.01;Oct-4 vs CD24,r=0.51,P＜0.01;Oct-4 vs CD44V6,r=0.39,P＜0.01;CD24 vs CD44v6,r=0.48,P＜0.01).
Conclusions PSCA,Oct-4,CD24 and CD44v6,as markers of cancer stem cells,played an important role in the carcinogenesis, progression,metastatic potency,invasive capability of gallbladder adenocarcinoma,and positive or high expression ones had poor prognostis The cancer stem cells in the cancer tissues might play an important role in the genesis,progression,biological behavior and prognosis of gallbladder adenocarcinoma.Detecting the PSCA,Oct-4,CD24 and CD44V6 levels in the benign lesions of gallbladder might have significant clinical values for the prevention and early-finding of gallbladder adenocarcinoma.
Part Two the Controlling Mechanism of Metastasis and Invasion of Gallbladder Adenocarcinoma
Chapter One Microvessels counts and lymph vessels counts and their significances in benign and malignant lesions of gallbladder
Objective To study the microvessel(MV)counts,and lymph vessel (LV)counts in gallbladder adenocarcinoma,peritumoral tissues, adenomatous polyp,and chronic cholecystitis,and to detect their clinicopathologic significances in gallbladder adenocarcinoma.
Methods Streptavidin-peroxidase immunohistochemical methods for MV and LV was used in the routinely paraffin-embedded sections(after 4%formaldehyde fixing)of specimens from gallbladder adenocarcinoma(n=108),peritumoral tissues(n=46),adenomatous polyp(n=15),and chronic cholecystitis(n=35).Selected ten regions tha MV and LV were most dense under the low-power field,and then counted the numbers of MV and LV of the ten regions under the high-power microscope;the average of the numbers was the counts of MV and LV of the case.
Results The counts of MV and LV(64.2±11.6,11.4±5.2)in gallbladder adenocarcinoma were significantly higher than those in peritumoral tissues(28.2±12.4,τ=17.6,P＜0.01;6.8±6.2,τ=4.63,P＜0.01), adenomat-ous polyp(32.4±11.8,τ=9.94,P＜0.01;5.6±2.9,τ=4.17, P＜0.01),and chronic cholecystitis(22.2±11.3,τ=18.26,P＜0.01;5.1±3.9, τ=6.63,P＜0.01).The counts of MV and LV were significantly lower in the cases of adenomatous canceration or well-differentiated adenocarcinoma,maximal diameter of mass＜2cm,no-metastasis of lymph node,and no-invasion of regional tissues than those in the ones of poorly-differentiated adenocarcinoma,maximal diameter of mass≥2cm, metastasis of lymph node,and invasion of regioonal tissues(P＜0.01). Significantly positive correlation was found between MV counts and LV counts in gallbladder adenocarcinoma(r=0.38,p＜0.01).
Conclusions MV counts and LV counts might be important biological markers reflecting the progression,clinical behavior and prognosis of gallbladder adenocarcinoma.
Chapter Two Study of metastatic controlling genes
Objective To study the expressions of KAI-1mRNA, Kiss-1mRNA,
MTA1 and CD146 in gallbladder adenocarcinoma,peritumoral tissues,adenomatous polyp,and chronic cholecystitis,and to detect their clinico- pathologic significances in gallbladder adenocarcinoma.
Methods In situ hybridization for staining KAI-1mRNA and Kiss-1mRNA,and immunohistochemical method of EnVision~(TM)(two steps)for MTA1 and CD146 were used in the routinely paraffin-embedded sections(after 4%formaldehyde fixing) of specimens from gallbladder adenocarcinoma(n=108),peritumoral tissues(n=46),adenomatous polyp(n=15),and chronic cholecystitis(n=35).
Results The positive rates of KAI-1mRNA and Kiss-1mRNA (51.9%,53.7%)were significantly lower in gallbladder adenocarcinoma than those in peritumoral tissues(KAI-1mRNA,80.4%,x~2=11.02, P＜0.01;Kiss-1mRNA,82.6%,x~2=11.48,P＜0.01),adenomatous polyp(KAI-1mRNA,86.7%,x~2=6.48,P＜0.05;Kiss-1mRNA,86.7%,x~ 2=5.86,P＜0.05);and chronic cholecystitis(KAI-1mRNA 85.7%,x~2=12.64, P＜0.01;Kiss-1mRNA,85.7%,x~2=11.44,P＜0.01).The positive rates of MTA1 and CD146(48.1%,53.7%)were significantly higher in gallbladder adenocarcinoma than those in peritumoral tissues(MTA1,26.1%,x~ 2=6.46,P＜0.05;CD146,30.4%,x~2=7.02,P＜0.01),ademomatous polyp(MTA,20.0%,x~2=4.22,P＜0.05;CD146,20.0%,x~2=8.59%, P＜0.01);and chronic cholecystitis(MTA1,8.6%,x~2=13.31,P＜0.01; CD146,5.7%,x~2=25.00,P＜0.01).The positive rates of KAI-1mRNA and kiss-1mRNA were significantly higher in cases with adenomafous canceration or well differentiated adenocarcinoma,maximal diameter of regional tissues＜2cm,no-metastasis of lgmph node and no-invasion of regional tissues than in those with poorly-differentiated adenocarcinoma or mucinous adenocarcinoma,maximal diameter of mass≥2cm, metastasis of lymph node and invasion of regional tissues(P＜0.05 or P＜0.01),while MTA and CD146 were on the contrary(P＜0.05 or P＜0.01).The counts of MV and LV in gallbladda adenocarcinoma were significantly lower in KAI-1mRNA and/on kiss-1mRNA positive cases than those in negative cases(P＜0.01),while the counts of MV and LV in gallbladder adenocarcinoma were significantly higher in MTA1,and/or CD146 positive cases than those in negative cases(P＜0.01).
Conclusions KAI-1mRNA,kiss-1mRNA,MTA1 and CD146 might be important biological markers reflecting the genesis,progression,clinic biological behavior and prognosis of gallbladder adenocarcinoma,and important markers controlling the metastasis and invasion abilities of gallbladder adenocarcinoma.Their controlling impact might correlate with their controlliny of the angiogenesis and lymphangiolgenesis of tumors.
目的研究胆囊腺癌、癌旁上皮、腺瘤性息肉和慢性胆囊炎组织中前列腺干细胞抗原(prostate stem cell antigen,PSCA)、Oct-4干细胞抗原(Oct-4)、CD24和CD_(44V)6表达水平,探讨其临床病理意义及在胆囊腺癌发生发展中的作用及作用机理。
方法108例胆囊腺癌、46例癌旁组织、15例腺瘤性息肉和35例慢性胆囊炎手术切除标本经4%甲醛固定后常规制作石蜡包埋切片,PSCA、Oct-4、CD24和CD_(44V)6染色方法均为Envision~(TM)免疫组化二步法。
结果(1)108例胆囊腺癌PSCA、Oct-4、CD24和CD_(44V)6表达阳性病例分别为59例(54.6%)、60例(55.6%)、57例(52.8%)和60例(55.6%),其评分值分别为2.09±1.94、2.06±1.86,2.43±1.65和2.52±1.60;46例癌旁组织PSCA、Oct-4、CD24和CD_(44V)6表达阳性病例分别为9例(19.6%)、10例(22.5%)、8例(17.4%)和9例(19.6%),其评分值分别为0.82±1.11、0.85±1.02、0.78±1.36和0.82±1.39;15例腺瘤性息肉PSCA、Oct-4、CD24和CD_(44V)6表达阳性病例分别为4例(26.7%)、3例(20.0%)、3例(20.0%)和4例(26.7%),其评分值分别为0.74±1.25、0.69±1.32、0.72±1.35和0.78±1.28;35例慢性胆囊炎PSCA、Oct-4、CD24和CD_(44V)6表达阳性病例分别为5例(14.3%)、5例(14.3%)、4例(11.4%)和6例(17.1%),其评分值分别为0.68±1.21、0.67±0.95、0.54±1.44和0.58±1.46;PSCA、Oct-4、CD24或(和)CD_(44V)6表达阳性的癌旁组织、腺瘤性息肉和慢性胆囊炎胆囊上皮均呈中度至重度不典型增生;胆囊腺癌PSCA、Oct-4、CD24和CD_(44V)6表达阳性率及其评分明显高于癌旁上皮(PSCA,x~2=10.09,P<0.01,τ=4.23,P.x~2<0.01 Oct-4,x~2=14.88,P<0.01,τ=4.32,P<0.01;CD24,x~2=16.58,P<0.01,τ=5.89,P<0.01;CD_(44V)6,x~2=16.90,P<0.01,τ=6.07,P<0.01)、腺瘤性息肉(PSCA,x~2=4.12,P<0.05,τ=2.60,P<0.05;Oct-4,x~2=6.66,P<0.01,τ=280,P<0.01;CD24,x~2=5.66,P<0.05,τ=3.78 P<0.01;CD_(44V)6,X~2=4.12,P<0.05,τ=4.05,P<0.01)和慢性胆囊炎(PSCA,X~2=17.40,P<0.01,τ=4.15,P<0.01;Oct-4,x~2=18.16,P<0.01,τ=4.21,P<0.01;CD24,x~2=18.48,P<0.01,τ=6.10,P<0.01;CD_(44V)6,x~2=15.69,τ=6.26,P(0.01)。
(2)腺瘤癌变或高分化腺癌、肿块最大径<2cm、无淋巴结转移及侵犯胆囊外周围组织器官病例PSCA、Oct-4、CD24和CD_(44V)6表达阳性率及其评分明显低于低分化腺癌、肿块最大径≥2cm、淋巴结转移及侵犯胆囊外周围组织器官病例,差异均有显著性或高度显著性(P<0.05或P<0.01)。
(3)胆囊腺癌中PSCA、Oct-4、CD24和CD_(44V)6表达水平相互之间具有高度一致性(P<0.01),其评分值相互之间存在密切正相关(PSCAvs Oct-4,r=0.44,P<0.01;PSCA vs CD24,r=0.36,P<0.01;PCSA vsCD_(44V)6,r=0.49;P<0.01,Oct-4 vs CD24,r=0.51,P<0.01;Oct-4 vsCD_(44V)6,r=0.39,P<0.01;CD24 vs CD_(44V)6,r=0.48,P<0.01)。
结论PSCA、Oct-4、CD24和CD_(44V)6作为癌干细胞标记物在胆囊腺癌发生、进展、转移及侵袭潜力方面具有重要作用,阳性或高水平表达者临床预后不良;癌组织中存在的癌干细胞有可能在胆囊腺癌发生发展中起重要作用,且影响胆囊腺癌临床生物学行为及其预后;检测胆囊良性病变组织中PSCA、Oct-4、CD24和CD_(44V)6 4种癌干细胞标记物表达水平对预防和早期发现胆囊癌可能具有重要临床应用价值。
第二部分胆囊腺癌转移和侵袭调控机制研究
第一章胆囊良恶性病变微血管和淋巴管计数及其意义
目的研究胆囊腺癌、癌旁组织、腺瘤性息肉和慢性胆囊炎组织中微血管(MV)和淋巴管(LV)计数及其临床病理意义。
方法108例胆囊腺癌、46例癌旁组织、15例腺瘤性息肉和35例慢性胆囊炎外科手术切除标本经4%甲醛固定后常规制作石蜡包埋切片,MV和LV染色方法均为S-P免疫组化法,低倍镜下选择MV和LV分布最丰富的10个区域,高倍镜下计数10个区域内MV和LV数,取其均值为该病例计数值。
结果108例胆囊腺癌MV和LV计数均值(64.2±11.6,11.4±5.2)明显高于癌旁组织(28.2±12.4,τ=17.6,P<0.01;6.8±6.2,τ=4.63,P<0.01)、腺瘤性息肉(32.4±11.8,τ=9.94,P<0.01;5.6±2.9,τ=4.17,P<0.01)和慢性胆囊炎(22.2±11.3,τ=18.26,P<0.01;5.1±3.9,τ=6.63,P<0.01)。腺瘤癌变或高分化腺癌、肿块最大径<2cm、无淋巴结转移及未侵犯周围组织器官病例MV和LV计数均值明显低于低分化腺癌、肿块最大径≥2cm、淋巴结转移及侵犯周围组织器官病例(P<0.01)。胆囊腺癌中MV计数与LV计数呈密切正相关(r=0.38,P<0.01)。
结论MV和LV计数可能是反映胆囊腺癌进展,临床生物学行为及预后的标记物
第二章转移抑制调控基因的研究
目的研究胆囊腺癌、癌旁组织、腺瘤性息肉和慢性胆囊炎组织中KAI-1mRNA、Kiss-1mRNA、MTA1和CD146表达水平及其临床病理意义。
方法108例胆囊腺癌、46例癌旁组织、15例腺瘤性息肉和35例慢性胆囊炎组织经4%甲醛固定后常规制作石蜡包埋切片,KAL-1mRNA和Kiss-1mRNA染色方法为原位杂交染色方法,MTA1和CD146染色方法为Envision~(TM)免疫组化二步法。
结果(1)胆囊腺癌KAL-1mRNA和Kiss-1mRNA表达阳性率(51.9%,53.7%)明显地低于癌旁组织(KAL-1mRNA,80.4%,x~2=11.02,P<0.01;Kiss-1mRNA,82.6%,x~2=11.48,P<0.01)腺瘤性息肉(KAL-1mRNA,86.7%,x~2=6.48,P<0.05;Kiss-1mRNA,86.7%,x~2=5.86P<0.05)和慢性胆囊炎(KAL-1mRNA,85.7%,x~2=12.64,P<0.01;Kiss-1mRNA,85.7%,x~(22)=11.44,P<0.01);胆囊腺癌MTA1和CD146表达阳性率(48.1%,53.7%)明显高于癌旁组织(MTA1,26.1%,x~2=6.46,P<0.05;CD146,30.4%,x~2=7.02,P<0.01),腺瘤性息肉(MTA1,20.0%,x~2=4.22,P<0.05;CD146,20.0%,x~2=8.59,P<0.01)和慢性胆囊炎(MTA1,8.6%,x~2=13.31,P<0.01,CD146,5.7%,x~2=25.00,P<0.01)。
(2)腺瘤癌变或高分化腺癌、肿块最大径<2cm、无淋巴结转移及未侵犯周围组织器官病例KAL-1mRNA、Kiss-1mRNA表达阳性率明显高于低分化腺癌、肿块最大径≥2cm、淋巴结转移及侵犯周围组织器官病例(P<0.05或P<0.01),但MTA1和CD146在胆囊腺癌中表达与KAL-1mRNA、Kiss-1mRNA表达相反(P<0.05或P<0.01)。
(3)KAL-1mRNA和/或Kiss-1mRNA表达阳性胆囊腺癌MV和LV计数明显低于阴性表达病例(P<0.01);MTA1和/或CD146表达阳性胆囊腺癌MV和LV计数明显高于阴性表达病例(P<0.01)。
结论KAL-1mRNA、Kiss-1mRNA、MTA1和CD146表达水平均为反映胆囊腺癌发生、进展,临床生物学行为及预后的重要分子标记物,均为重要的调控胆囊癌等恶性肿瘤转移和侵袭能力的重要指标,其作用可能与调控肿瘤血管生成和淋巴生成有关。
Part One Cancer Stem Cells and Their Markers
Objective To study the expression levels of prostate stem cell antigen(PSCA),Oct-4,CD24 and CD44V6 in the gallbladder adenocarcinoma,perirumoral tissues,adenomatous polyp,and chronic cholecystitis,and to detect their clinicopathologic significances in gallbladder adenocarcinoma.
Methods Immunohistocemical method of EnVision~(TM)(two steps)for PSCA,Oct-4,CD24 and CD44V6 was used in the routinely paraffin-embedded sections(after 4%formaldehyde fixing)of specimens from gallbladder adenocarcinoma(n=108),peritumoral tissues(n=46), adenomatous polyp(n=15),and chronic cholecystitis(n=35)
Results(1) In the 108 cases of gallbladder adenocarcinoma,PSCA, Oct-4,CD24 and CD44V6 positive cases were respectively 59(54.6%),60 (55.6%),60(55.6),57(52.8%),and 60(55.6%),and their scores were respectively2.09±1.94,2.06±1.86,2.43±1.65,and 2.52±1.60.In the 46 cases of perirumoral tissues,PSCA,Oct-4,CD24 and CD44V6 positive cases were respectively 9(19.6%);10(22.5%);8(17.4%),and 9 (19.6%),their scores were respectively 0.82±1.11 0.85±1.02 0.78±1.36 and 0.82±1.39.In the 15 cases of adenomatous polyp,PSCA,Oct-4,CD24 and CD44V6 positive cases were respectively 4(26.7%),3(20%),and 4 (26.7%) and their scores were respectively 0.74±1.25,0.69±1.32, 0.72±1.35,and 0.78±1.28 In the 35 cases of chronic cholecystitis,PSCA,oct-4,CD24,and.CD44V6 positive cases were respectively 5(14.3%) 5(14.3%) 4(14.4%) and 6(17.1%),and their scores were respectively 0.68±1.21,0.67±0.95,0.54±1.44,and 0.58±1.46, The gallbladder epithelium of PSCA,Oct-4,CD24 and CD44V6 positive cases all showed middle to severely-atypical hyperplasia.The positive rates of PSCA,ct-4,CD24 and CD44V6 expressions and their scores in gallbladder adenocarcinoma were significantly higher than those in peritumoral tissues(PSCA,x~2=10.09,P＜0.01,τ=4.23,P＜0.01;Oct-4, x~2=14.88,P＜0.01,τ=4.32,P＜0.01;CD24,x~2=16.58,p＜0.01,t=5.89, P＜0.01;CD44V6,x~2=16.90,P＜0.01,τ=6.07,P＜0.01),adenomatous polyp (PSCA,x~2=4.12,P＜0.05;τ=2.60P＜0.05 Oct-4,x~2=6.66,p＜0.01,τ=2.80, P＜0.01;CD24,x~2=5.66,P＜0.05,τ=3.78,P＜0.01;CD44V6,x~2=4.12, P＜0.05,τ=4.05,P＜0.01),and chronic cholecystitis(PSCA,x~2=17.40, P＜0.01,τ=6.10,P＜0.01;Oct-4,x~2=18.16,p＜0.01,τ=4.21,P＜0.01;CD24, x~2=18.48,P＜0.01,τ=6.10,P＜0.01;CD44v6,x~2=15.69,P＜0.01,τ=6.62, P＜0.01).
(2)The positive rates of PSCA,Oct-4,CD24 and CD44V6 expressions and their scores were significantly lower in the cases of adenomatous canceration or well-differentiated adenocarcinoma,maximal diameter of mass＜2cm,no-metastasis of lymph node,and no-invasion of regional tissues than those in the ones of pooly-differentiated adenocarcinoma, maximal diameter of mass≥2cm,metastasis of lymph node and invasion of regional tissues(P＜0.05,or P＜0.01).
(3)Highly consistencies in PSCA,Oct-4,CD24 and CD44V6 expressions were found in gallbladder adenocarcinoma(P＜0.01),and significantly positive correlations were found among their scores(PSCA vs Oct-4,r=0.44,P＜0.01;PSCA vs CD24,r=0.36,P＜0.01;PSCA vs CD44V6,r=0.49,P＜0.01;Oct-4 vs CD24,r=0.51,P＜0.01;Oct-4 vs CD44V6,r=0.39,P＜0.01;CD24 vs CD44v6,r=0.48,P＜0.01).
Conclusions PSCA,Oct-4,CD24 and CD44v6,as markers of cancer stem cells,played an important role in the carcinogenesis, progression,metastatic potency,invasive capability of gallbladder adenocarcinoma,and positive or high expression ones had poor prognostis The cancer stem cells in the cancer tissues might play an important role in the genesis,progression,biological behavior and prognosis of gallbladder adenocarcinoma.Detecting the PSCA,Oct-4,CD24 and CD44V6 levels in the benign lesions of gallbladder might have significant clinical values for the prevention and early-finding of gallbladder adenocarcinoma.
Part Two the Controlling Mechanism of Metastasis and Invasion of Gallbladder Adenocarcinoma
Chapter One Microvessels counts and lymph vessels counts and their significances in benign and malignant lesions of gallbladder
Objective To study the microvessel(MV)counts,and lymph vessel (LV)counts in gallbladder adenocarcinoma,peritumoral tissues, adenomatous polyp,and chronic cholecystitis,and to detect their clinicopathologic significances in gallbladder adenocarcinoma.
Methods Streptavidin-peroxidase immunohistochemical methods for MV and LV was used in the routinely paraffin-embedded sections(after 4%formaldehyde fixing)of specimens from gallbladder adenocarcinoma(n=108),peritumoral tissues(n=46),adenomatous polyp(n=15),and chronic cholecystitis(n=35).Selected ten regions tha MV and LV were most dense under the low-power field,and then counted the numbers of MV and LV of the ten regions under the high-power microscope;the average of the numbers was the counts of MV and LV of the case.
Results The counts of MV and LV(64.2±11.6,11.4±5.2)in gallbladder adenocarcinoma were significantly higher than those in peritumoral tissues(28.2±12.4,τ=17.6,P＜0.01;6.8±6.2,τ=4.63,P＜0.01), adenomat-ous polyp(32.4±11.8,τ=9.94,P＜0.01;5.6±2.9,τ=4.17, P＜0.01),and chronic cholecystitis(22.2±11.3,τ=18.26,P＜0.01;5.1±3.9, τ=6.63,P＜0.01).The counts of MV and LV were significantly lower in the cases of adenomatous canceration or well-differentiated adenocarcinoma,maximal diameter of mass＜2cm,no-metastasis of lymph node,and no-invasion of regional tissues than those in the ones of poorly-differentiated adenocarcinoma,maximal diameter of mass≥2cm, metastasis of lymph node,and invasion of regioonal tissues(P＜0.01). Significantly positive correlation was found between MV counts and LV counts in gallbladder adenocarcinoma(r=0.38,p＜0.01).
Conclusions MV counts and LV counts might be important biological markers reflecting the progression,clinical behavior and prognosis of gallbladder adenocarcinoma.
Chapter Two Study of metastatic controlling genes
Objective To study the expressions of KAI-1mRNA, Kiss-1mRNA,
MTA1 and CD146 in gallbladder adenocarcinoma,peritumoral tissues,adenomatous polyp,and chronic cholecystitis,and to detect their clinico- pathologic significances in gallbladder adenocarcinoma.
Methods In situ hybridization for staining KAI-1mRNA and Kiss-1mRNA,and immunohistochemical method of EnVision~(TM)(two steps)for MTA1 and CD146 were used in the routinely paraffin-embedded sections(after 4%formaldehyde fixing) of specimens from gallbladder adenocarcinoma(n=108),peritumoral tissues(n=46),adenomatous polyp(n=15),and chronic cholecystitis(n=35).
Results The positive rates of KAI-1mRNA and Kiss-1mRNA (51.9%,53.7%)were significantly lower in gallbladder adenocarcinoma than those in peritumoral tissues(KAI-1mRNA,80.4%,x~2=11.02, P＜0.01;Kiss-1mRNA,82.6%,x~2=11.48,P＜0.01),adenomatous polyp(KAI-1mRNA,86.7%,x~2=6.48,P＜0.05;Kiss-1mRNA,86.7%,x~ 2=5.86,P＜0.05);and chronic cholecystitis(KAI-1mRNA 85.7%,x~2=12.64, P＜0.01;Kiss-1mRNA,85.7%,x~2=11.44,P＜0.01).The positive rates of MTA1 and CD146(48.1%,53.7%)were significantly higher in gallbladder adenocarcinoma than those in peritumoral tissues(MTA1,26.1%,x~ 2=6.46,P＜0.05;CD146,30.4%,x~2=7.02,P＜0.01),ademomatous polyp(MTA,20.0%,x~2=4.22,P＜0.05;CD146,20.0%,x~2=8.59%, P＜0.01);and chronic cholecystitis(MTA1,8.6%,x~2=13.31,P＜0.01; CD146,5.7%,x~2=25.00,P＜0.01).The positive rates of KAI-1mRNA and kiss-1mRNA were significantly higher in cases with adenomafous canceration or well differentiated adenocarcinoma,maximal diameter of regional tissues＜2cm,no-metastasis of lgmph node and no-invasion of regional tissues than in those with poorly-differentiated adenocarcinoma or mucinous adenocarcinoma,maximal diameter of mass≥2cm, metastasis of lymph node and invasion of regional tissues(P＜0.05 or P＜0.01),while MTA and CD146 were on the contrary(P＜0.05 or P＜0.01).The counts of MV and LV in gallbladda adenocarcinoma were significantly lower in KAI-1mRNA and/on kiss-1mRNA positive cases than those in negative cases(P＜0.01),while the counts of MV and LV in gallbladder adenocarcinoma were significantly higher in MTA1,and/or CD146 positive cases than those in negative cases(P＜0.01).
Conclusions KAI-1mRNA,kiss-1mRNA,MTA1 and CD146 might be important biological markers reflecting the genesis,progression,clinic biological behavior and prognosis of gallbladder adenocarcinoma,and important markers controlling the metastasis and invasion abilities of gallbladder adenocarcinoma.Their controlling impact might correlate with their controlliny of the angiogenesis and lymphangiolgenesis of tumors.
引文
[1]Anton Aparicio LM,Cassinello Espinosa J,Garcia Campelo R,etal. Prostate carcinoma and stem cells.Clin Transl Oncol, 2007,9(2):66-76
[2]Collins AT, Berry PS, Hyde C,etal. Prospective identification of tumorigenic prostate cancer stemcells.Cancer Res 2005,65(23):10946-10951
[3]Chang CC. Recent translational research:stem cells as the root of breast cancer. Breast Cancer Res, 2006, 8(l):103-113
[4]O'Brien CA, Pollett A, Gallinger S,etal.A human colon cancer stem cells capable of intiating tumor growth in immunodeficient mice.Nature 2007,445(7123): 106-110
[5] Ricci-vitianill,Lombard L, DG,Pilozzi E,etal.Identification and expansion of human colon-cancer-initiating cells. Nature, 2007,445(7123): 111-115.
[6]Saqiv E,Kazanov D,Arber N. CD24 plays an important role in the carcinogenesis process of pancreas. Biomed Pharmacother, 2006,60(6):280-284
[7] Li C, Heidt DG, Dalerba P, etal. Identification of pancreatic cancer stem cells. Cancer Res, 2007, 67(3): 1030-1037
[8]Prince ME, Sivanande R, Kaczorowski A,etal.Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.Pror Natl Acad Sci USA 2007,104(3):973-978
[9] Lou H, Dean M.Targeted therapy for cancer stem cells:the patched pathway and ABC transporters. Oncogene 2007,20(9):1357-1360
[10] Pellicano R,Smedile A,Saracco G,et al,Stem cells and helicobacter-induced gastric cancer:where do we stand at the end of 2006. Panminerra Med 2006,48(3): 175-179
[11] Piscaglia AC,Shupe TD,Petersen BE,etal.Stem cells,cancer,liver,and liver cancer stem cells:finding a way out of the ladyrinth...Curr Cancer Drug Targets,2007,7(6):582-590
[12]Ma S,Chan KW,Hu L,et al.Identification and characterization of turmorigenic liver cancer stem /progenitor cells.Gastroenterology,2007,132(7):2542-2556
[13]Zhiyang Z,Wenlu S.External beam radiotherapy(EBRT)suppressed prostate stem cell antigen(PSCA)mRNA expression in clinically localizd prostate cancer.Prostate 2007,67(6):653-660
[14]Grubbs EG,Abdel-wahab Z,Tyler DS,etal.Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer.Ann Surg Oncol 2006,13(12):1645-1654
[15]郎根强,孙颖浩.前列腺干细胞抗原与前列腺癌,国外医学泌尿系统分册,2002,22(5):280-282
[16]喻燕波、王共先.前列腺干细胞抗原研究进展,江西医学院学报2004,44(1):117-119
[17]张向阳,曾强,祖雄兵等.前列腺干细胞抗原在前列腺癌中的表达及其临床意义.中国现代医学杂志,2007,17(15):1856-1859
[18]Joung JY,Yang SO,Jeong IG,etal.Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer:potential value in molecular staging of prostate cancer,Int J Urol,2007,14(7):635-643
[19]Zhigang Z,Wenlu S.Prostate stem cell antigen(PSCA)mRNA expression in prostatic intraepitheliat neoplasia:implication for the development of prostate cancer,Prostate 2007,67(11):1143-1151
[20]Trosko TE.From adult stem cell to cancer stem cells:Oct-4 gene,cell-cell communication,and hormone during tumor promotion,Ann Natl Acad Sci 2006,1089(1):36-58
[21]Roman GThe role of adult stem cells in carcinogenesis.Drug New Perspect,2005,18(9):555-559
[22]Atlasi Y,Mowla SJ,Ziaee SA,etal.Oct-4,an embryonic stem cell marker,is highly expressed in bladder cancer,Int J Cancer 2007,120(7):1598-1602
[23]Kruse C,Kajahn J,Perschnik AE,et al.Adult pancreatic stem/progenitor cells spontaneously differentiate in vitro into multiple cell lineages and form teratoma like structures.Ann Anat,2006,188(6):503-517
[24]Palumba C,van Roozendaal K,Gillis AJ,etal.Expression of the PDGF alpha-receptor 1.5kb transcript,Oct-4,and C-KIT in human normal and malignant tissues.Implications for the early diagnosis of testicular germ cell tumors and for our understanding of regulatory mechanisms.J Pathol,2002,196(4):467-477
[25]严宁、张汉东、宋娟等.口腔鳞癌组织中转录因子Oct-4的表达及其与肿瘤干细胞相关性研究,临床口腔医学杂志,2006,22(11):664-666
[26]范姝君,李连宏,张众.Oct-4与生殖细胞及其肿瘤的关系,临床与实验病理学杂志,2005,21(5):609-611
[27]庄建良,苏子剑,许荣誉.CD24与肿瘤侵袭转移的关系,国际病理科学与临床杂志2006,26(5):387-390
[28]郝丽,张雁云.粘附分子CD24在肿瘤转移中的作用.细胞生物学杂志,2006,28(A):421-424
[29]庄建良,苏子剑,潘群雄等.大肠癌CD24的表达及其与肿瘤细胞增殖和血管形成的关系,世界华人消杂志,2007,15(3):260-265
[30]张永红,曾甫清.肾细胞癌中CD24蛋白的表达及其临床意义,临床泌尿外科杂志,2007,22(3):219-220
[31]Kristiansen G,Demkert C,Xchluns K.CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.Am J Pathol 2002,161(11):1215-1221
[32]Kristiansen G,Winzer KJ.CD24 expression is a new prognostic marker in breast cancer.Clin Canncer Res,2003,15(9):4906-4913
[33]Su MG,Hsu C,Kao HL,etal.CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma.Cancer Lett,2006,235(1):34-39
[34]Jacob J,Bellach J,Grutzmann R,etal.Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades.Pancreatology,2004,4(4);454-460
[35]Choi YL,Lee SH,Kwon GY,et al,Overexpression of CD24:association with invasiveness in urothelial carcinoma of the bladder.Arch Pathol Lab Med,2007,131 (3):275-281
[36]Liu R,Wang X,Chen GY?etal,CD24 expression is a poor prognostic marker in endomerrial carcinoma.N Engl J med,2007,356(2):217-226
[37]Karaha N,Gunev M,Oral B,etai,CD24 expression is a poor prognostic marker in endomerrial carcinoma.Eur J Gynaeco Oncol,2006,27(5):500-504
[38]Winkler A,Zigeuner R,Rehakp P,etal.CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumor progression.Virchews Arch,2007,450(1):59-64
[39]马丹,张珍祥,徐永健.变异型CD44分子和癌细胞的侵袭及转移.国际呼吸杂志2007,27(6):466-469
[40]罗永富,王化修,宋海鹏等.122例甲状腺癌CD44V6检测结果分析.中医药导报2007,13(1):74-75
[41]范伟,孙钦迎.大肠癌中SLe-x和CD44V6基因蛋白表达的研究,中国老年医学杂志,2007,27(6):466-469
[42]常瑞霞,肖鹏,邢燕红.CD44V6在卵巢上皮性肿瘤的表达及临床意义.长治医学院学报,2006,20(1):9-11
[43]贺雅莉,许双塔,黄旭.宫颈癌中CD44V6的表达及其临床意义.湖北医学,2007,13(1):15-17
[44]梅静,陈古福,PgP和CD44V6在胃癌中的表达及其临床意义,皖南医学院学报,2007,26(1):46-48
[45]杨艳娟,程德云,李熙霞等.骨桥蛋白OPN和粘附分子CD44V6在肺癌中表达.中国肺癌杂志,2007,10(3):189-192
[46]郑核,钟德许,苗雄鹰.CD44V5,CD44V6在胆囊癌组织中的表达研究,中国现代手术学杂志,2006,10(3):189-192
[47]Joo M,Lee Hk,Kang YK,Expression of E-cadherin,beta-catenin,CD44 and CD44V6 in gastric adenocarcinoma:relationship with lymph node metastasis.AnticancerRes,2003,23(2B):1581-1588
[48]Bendarda R,Algars A,Elzagheid A,etal.Comparison of CD44 expression in primary tumours and colorectal cancer.Oncol Rep,2006,16(4):741-746
[49]Gotodu T,Matsumura Y,Kondo H,et al.Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res 1998, 89 (10):1033-1040
[50] Berner HS, Suo Z, Risberg B,etal. Clinicopathological association of CD44V6-mRNA and protein expression in primary breast carcinomas. Histopathology 2003, 42(6):546-554
[51] Yanagis a wa N, Mikmi; T, Mitomi H,et al,CD44 variant Overexpression in gallbladder carcinoma associated with tumor dedifferentiation.Cancer 2001, 91 (2):408-416
[52]Choi YI, Xuan YH, Shin YK, etal.An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions. J Histochem Cytochem 2004, 52(5):591-601
[53] Harper LJ, Piper K, Common J,et al. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma.J Oral Pathol Med 2007,36(10):594-603
[54]Mailtland NT,Bryce SE, Stower MJ,etal.Prostate cancer stem cells:a target for new therapies.Emst Schering Found Symp Proc,2006,5(2):155-179
[55] Farnie G, Clarke RB. Breast stem cells and cancer. Ernst Schering Found Symp Proc, 2006,5(2):141-153
[56] Kakarala M, Wicha MS. Cancer stem cells: implications for cancer treatment and prevention. Cancer J, 2007,13(5):271-275
[57] Said J. Biomarker discovery in urogenital cancer. Biomarkers,2005,S-10: S83-86
[58] Wente MN, Jain A, Kono E, etal. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 2005,31 (2): 119-125
[59] Tricdi JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression;current and future diagnostic markers. Clin Cancer Res 2004, 10 (12ptl): 3943-3953.
[60] Elsamman EM, Fukumori T, Dasai T, etal, Prostate stem cell antigen predicts tumor recurrence in superfical transitional cell carcinoma of urinary bladder.BJU Int 2006, 97(6): 1202-1207
[61] Elsamman EM, Fukumor T, Tanmoto S, et al, The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantiative reverse transcriptase-polymerase chain reaction analysis.BJU Int 2006,98(3):668-673
[62] Arnott D, Kishiyama A, Luis EA, etal. Selective detection of membrance proteins without antibodies: a mass spectrometric version of the western blot. Mol Cell Protemics,2002,l(2):148-156
[63] Tai MH, Chang CC, Kiupel M, etal. Oct-4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis, 2005,26(2):495-502
[64] Altasi Y, Mewla SJ, Ziaee SA,etal. Oct-4, an embryonic stem cell marker, is highly expressed in bladder Cancer. Int J cancer 2007,120(7): 1598-1602
[65] Ponti D, Costa A, Zaffaroni N, etal. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005,65(13):5506-5511
[66] Baker PM, Oliva E. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumor: an update. Int J Gynecol Pathol 2005,24(l):39-55
[1] Dong JT, Lamb PW, Rinker-schaeffer CW, et al. KA1-1, a metastasis supressor gene for prostate cancer on human chromosome 11 pl1.2. Science 1995, 268, 52(12):884-886.
[2] Leavey PJ, Timmons C, Frawley W, et al. KA1-1 expression in pediatric high-grade osteosarcoma. Pediatr Dev Pathol, 2006,9(3):219-224.
[3] Ito Y, Uruno T, Takamura Y, et al. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology, 2005, 68(2-3):87-96.
[4] Guo XZ, Friess H, Shao X D, et al. KA1-1 gene is differently expressed in papillary and pancreatic cancer: influence on metastasis. World J Gastroenterol, 2000, 6(6).866-871.
[5]Ward M,Konishi N,Ohshima M,et al.Expression of KA1-1 in paraffin-embedded normal,hyperplastic and neoplastic prostate and prostate carcinoma cell line.Pathol Int 1998,48:87-92.
[6]Yang X,Welch DR,Phillips KK,et al.KA1-1,a putative marker for metastastic potential in human breast cancer.Cancer Lett,1997,11(s):149-155.
[7]Sun HC,Tang Z Y,Zhou G,et al.KA1-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases.J Exp Clin Cancer Res,1998,17(3):307-311.
[8]Kim JH,Kim B,Cai L,et al.Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.Nature,2005,434(7035):921-926.
[9]Martin TA,Watkins G,Jinag WG,et al.Kiss-1 expression in human breast cancer.Clin Exp Metastasis,2005,22(6):503-511.
[10]Dhar DK,Naora H,Kubota H,et al.Downregulation of Kiss-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma.Int J Cancer,2004,111(6):868-872.
[11]Ikeguchi M,Yamaguchi K,Kaibara N.Clinical significance of the loss of kiss-1 and orphan G-protenn-coupled receptor(hoT7T175) gene expression in esophageal squamous cell carcinoma.Clin Cancer Res,2004,10(4):1379-1383.
[12]Sanchez-carbayo M,Capodieci P,Cordon-cardo C.Tumor suppressor role of kiss-1 in bladder cancer:loss of kiss-1 experssion is associated with bladder cancer progression and clinical outcome.Am J Pathol,2003,162(2):609-617.
[13]张辉,赵丹懿,宋永胜.Kiss-1基因在肾癌中的表达及对细胞侵袭力的影响.中国医科大学学报,2007,36(2):171-172.
[14]梁珊,杨竹林.大鼠胰腺癌和非癌胰腺组织的Kiss-1mRNA表达。中南大学学报(医学板)2007,32(1):109-113.
[15]候元凯,王义,丛文铭等.肿瘤转移抑制基因Kiss-1和基质金属蛋白酶-9在肝细胞癌门静脉癌栓中的表达.癌症.2007,26(6):591-595.
[16]Pencil SD,Toh Y,Nicolson GL.Candiadte metastasis-assciated genes of the rat13762 NF mammary adenocarcinoma.Breast Res Treat,1993,25(2):165-174.
[17]Roepman P,deJager A,Grootkoerkamp M J,et al.Maintenance of head and neck tumor gene expression profiles upon lymph node metastasis.Cancer Res,2006,66(23):1110-1114.
[18]Balasenthil S,Broaddus RR,Kumar R.Expression of metastasis-associated protein-1(MTA1) in benign endometrium and endometrial adenocarcinomas.Hum Pathol,2006,37(6):656-661.
[19]Jang KS,Paik SS,Chung H,et al.MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancer.Cancer Sci,2006,97(5):374-379.
[20]Toh Y,Kuwano H,Mori M,et al.Overexpression of metastasis-assocated MTA1 mRANA in invasive oesophageal carcinomas.Br J Cancer,1999,79(11-12)L1723-1726.
[21]Toh Y,Oki E,Oda S,et al.Overexpression of the MTA1 gene in gastrointestinal carcinomas.correlation with invasion and metastasis.Int J Cancer,1997,74(4):459-463.
[22]Sasaki H,Moriyama S,Nakashima Y,et al.Expression of the MTAlmRNA in advanced lung cancer.Lung Cancer,2002,35(2):149-154.
[23]刘运肾,胡亚翎,刘菊梅等,肺癌PTEN,MTAl、P73表达与预后相关性.蚌埠医学院学报,2005,30(6):526-528.
[24]林川,陈汉,吴孟超等.中瘤转移基因MTAl在原发性肝癌中的表达及其临床意义.中华外科杂志,2000,38(12):915-917.
[25]Garcia S,Dales TP,Charafe-Jaccffret E,et al.Poor prognosis in breast carcinoma correlates with increased expression of targetable CD146 and C-Met and with proteomic basal-like phenotype.Hum Pathol,2007,38(6):830-841.
[26]Loges S,Clausen H,Reichelt V,et al.Determination of microvessel density by quantiative real-time PCR in esophageal cancer:correlation with histologic methods,angiogenic growth factor expression,and lymphnode metastasis.Clin Cancer Res,2007,13(1):76-80.
[27]Watson-Hurst K,Becker D.The role of N-cadherin,MCAM and beta 3integrin in melanoma progression,proliferation,migration and invasion.Cancer Biol Ther,2006,5(10):1375-1382
[28]Aldovini D,Demichelis F,Doglioni C,et al.MCAM expression as marker of prognosis in epithelial ovarian cancer.Int J Cancer,2006,119(8):1920-1926.
[29]Wu GJ,Varma VA,Wu MW,et al.Expression of a human cell adhesion molecule,MUC18,in prostate cancer cell lines and tissues.Prostate 2001,48(4):305-315.
[30]王起武,查斌,王章才.CD146及肿瘤微血管密度与前列腺癌关系的研究.皖南医院学2007,26(2):97-103.
[31]李丽萍,杨春,曹骥等.CD146mRNA在人肝细胞癌组织中的表达及其意义.现代肿瘤病学杂志,2006,14(12):1567-1570.
[32]Wright MD,Tomlinson MG.The ins and outs of the tran:membrane 4superfamily.Immunol Today,1994,15(12):588-594.
[33]Friess H,Guo XZ,Berberat P,et al.Reduced KA1-1 expression in pancreatic cancer is associated with lymph node and distant metastasis.Int J Cancer 1998,79(3):349-355.
[34]Sho M,Adachi M,Taki T,et al.Tran:membrane 4 superfamily as a progrostic factor in pancreatic cancer.Int J Cancer 1998,75(5):509-516.
[35]Dong JT,Suzuki H,Pin SD,et al.Down-regulation of the KA1-1 metastatic cancer in frequently involves gene mutation sr allelic loss.Cancer Res 1996,56(14):4387-4390.
[36]Miyazaki T,Kato H,Shitara y,et al.Mutation and expression of the metastasis suppressor squamous cell carcinoma.Cancer,2000,89:955-962.
[37]陈刚,陈森清,张晓梅等.Kai-1基因外显子缺失与大肠癌的临床关系.南京医科大学(自然科学版),2007,27(6)":594-597.
[38]孟丽辉,辛彦,吴东瑛等。胃癌组织KAl-1和nm23-H1蛋白的表达意义.世界华人消化杂志,2005,13(23):2726-2730.
[39]Lee JH,Micle ME,Hcks DJ,et al.Kiss-1,a novel human malignants melanoma metastasis-suppressor gene.Natl Cancer Inst 1996,88(23):1731-1737.
[40]Ohtaki T,Shintani Y,Honda S,et al.Metastasis suppressor gene kiss-1encodes peptide ligand of a G-protein-Cupled receptor.Nature,2001,411 (68370):613-617.
[41]Goldberg SF,Micle ME,Hata N,et al.Melanoma metastasis suppression by chromosome 6:evidence for a pathway regulated by CRSP3 and TXNIP.Cancer Res,2003,63(2):432-440.
[42]Yan C,Wang H,Beyd DD.Kiss-1 represses 92-KDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha-induced block of p65/p50 nudear transcocation.J Biol Chem,2001,276(2):1164-1172.
[43]Takino T,Koshikawa N,Miyamori H,et al.Cleavage of metastasis suppressor gene protein kiss-1 protein/metastin by matrix metalloproteniases.Oncogene,2003,22(30):4617-4626.
[44]Shirasaki F,Takao M,Hata N,et al.Loss of expression of metastasis suppressor gene kiss-1 during melanoma progression and its association with LOH of chromosome 6q~16.3-q~23.Cancer Res,2001,61(20):7422-7425.
[45]Masui T,Doi R,Mori T,et al.Metastin and its variant forms suppress migration of pancreatic cancer cells.Biochem Biophys Res Commun,2004,315(1):85-92.
[46]姚容亮,杨竹林,李永国等.转移抑制基因Kiss-1和KAl-1在胃癌组织中表达的原位杂交研究.中华胃肠外科杂志,2007,1O(3):274-277.
[47]王春晖,乔宠,戴显伟.人胰腺癌Kiss-1基因mRNA表达及其临床意义.中国肿瘤防治杂志,2006,13(3):207-210.
[48]柴丽,石林祥,房林等.Kiss-1基因及其受体在乳腺癌中的表达及临床意义.中华实验外科杂志,2005,22(9):1068-1070.
[49]Toh Y,Pencil SD,Nicloson GL.A novel candidate metastasis-assciatel gene,mtal,differentially expressed in high metastatic mammary adenocarcinoma cell lines.J Biol Chem,1994,269(37):22958-22963.
[50]Talakder AH,Mishra SK,Mandal M.MTA1 interacts with MAT1,a cyclin-depondent kinase-actuvating kinase complex ring finger factor,and regulates estrogen receptor transactivation functions.J Biol Chem,2003,178(13):11676-1685.
[51]Iguchi H,Imura G,Toh Y,et al.Expression of mtal,a metastasis-associated gene with histone deacetyase activity in pancreatic cancer.Int J Oncol,2002,16
[52]唐正严,祖雄兵,齐琳等.膀胱移行细胞癌Mta-1基因与蛋白表达及其临床意义.临床泌尿外科杂志,2006,21(8):595-597.
[53]李丽萍,曹骥,杨春.CD146与肿瘤的关系.中华肿瘤防治杂志,2007,14(8):635-637.
[54]Bittner M,Meltzer P,Chen Y,et al.Molecular classification of cutaneous malignant melanoma by gene expression profiling.Nature,2000,406(6795):536-540.
[55]Kristiansen G,Yu Y,Schluns K,et al.Expression of the cell adhesion moleule CD146/MCAM in non-small cell lung cancer,Anal Cell Pathol,2003,25(2):77-81.
[56]Shih IM,Hsu MY,Palazzo J P,et al.The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma.Am J Pathol,1997,151(3):745-751.
1.Anton Aparicio LM,et al.Prostate careinoma and stem cells.Clin Transl Oncol 2007,9(2):66-76.
2.Collins AT,et al.Prospective identification of tunnorigenic prostate cancer stem cells.Cancer Res 2005,65(23):1049-1095.
3.ChanCC.Recent translational research:stem cells a the root of breast cancer.Breast cancer Res,2006,8(1):103-113.
4.O'Brien CA,et al.A human colon cancer stem cells capable of intitating tumor growth in immunodeficient mice.Nature 2007,445(7123):106-110.
5.Saqiv E,etal.CD24 plays an important role in the carcinogenesis process of parcreas.Biomed pharaamother 2006,60(6):280-284.
6.Li C,et al Identification of pancreatic cancer stem cells.Cancer Res 2007,67(3):1030-1037.
7.Prince ME,et al.Identification of a subopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.Proic Natl Acod Sci VSA2007,104(3):973-978.
8.Lou H,et al.Targeted therapy for cancer stem cells:the patched pathway and ABC transporters.Qncogene 2007,20(9):1357-1360.
9.Pellican R,et al stem cells and helicobacter-induced gastric calleer.Where do we stand at the end of 2006.Panminerra Med 2006,48(3):175-179.
10.Piscaglia AC,et al.stem cells,cancer,liver,and liver cancer stem cells:finding a way out of the Ladyrinth…….Curr cancer Drug Targets 2007,7(6)582-596.
11.Ma S et al.Identification and characterization of tumerigenic liver cancer stem/progenitor cells.Gastroenterology 2007,132(7):2542-2556.Kong DS,et al.The progression of gliomas is associated with cancer stem cell phenotype.Oncol Rep 2008,19(3):639-643.
12.喻燕波等,前列腺于细胞抗原研究进展,江西医学院学报2004,44(1):117-119.
13.朗根强等,前裂腺干细胞抗原与前列腺癌,国外医学泌尿系统分册,2002,22(5):280-282.
14.Zhiyang z,et al.Prostate stem cell antigen(PSCA)mRNA expression in prostatic intraepithelial neoploasia:implication for the development of prostate cancer.Prostate 2007,67(11):1143-1151.
15.young JY,et al.Reverse transcriptase-polymerase chain lieaction and immuno-histochemical studies for deteertion of prostate stem cell antigen expression in prostate cancer:potential value in molecular staging of prostate cancer.Int J Urol 2007,14(7):635-643.
16.Grubb EG,et al.Vtilizing quantitative polgmerase chain reaction to eraluate prostate stem cell antigen as a tumor marher in pancreatic cancer:Ann Surg Oncol 206,13(12):1645-1654.
17.Trosko TE,et al.From adult stem cell to cancer stem cells.Oct-4 gene,cell-cell communication,and hormone during tumor promotion.Ann Natl Acad Sci 2006,1089(1):36-58.
18.Roman G The role of adut stem cells in carcinogenesis.Drug New perspect 2005,18(9):555-559.
19.Atlasi Y,et al.Oct-4,an embryonic stem cell marker,is highly expressed in bladder cancer.Int J Cancer 2007,120(7):1598-1602.
20.严宁等,口腔鳞癌组织中转录因子Oct-4的表达及其与肿瘤干细胞相关性研究,临床口腔医学杂志,2006,22(11):664-666.
21.范姝君等,Oct-4与生殖细胞及其肿瘤的关系,临床实验病理学杂志,2005,21(5):609-611.
22.庄建良,等.CD24与肿瘤侵袭转移的关系,国际病理科学与临床杂志,2006,26(5):387-390
23.郝丽等,粘附分子CD24在肿瘤转移中的作用,细胞生物学杂志,2006,28(A):421-424。
24.Kristiansen G,et al.CD24 is expressed in ovarian Cancer and is a new independent grognostic marker of patient survival.Am J pathrel 2002,161(1):1215-1221.
25.Kristiansen G,et al CD24 expression is a new prognostic morker in breast cancer.Clin cancer Res.2003,15(9):4906-4913.
26.Jacob J,et al.Expression of CD24 in adenocarcinomas of the pancreas correlates with higher rumor grades.Pancreatology 2004,4(4):454-460.
27.马丹等,变异型CD44分子和癌细胞的侵袭及转移,国际呼吸杂志2007,27(6):466-469.
28.JooM,et al Expression of E-cadherin,beta-catenin,CD44 and CD44V6 in gastric adeno-carcinoma:relationship with lymphnode metastasis.Anticancer Res 2003,23(2B):1581-1588.
29.Bendarda R,etal comparision of CD44 expression in primary tumors and coloretal cancer.oncd Rep,2006,16(4):741-146.
30.Berner Hs,etal clinicopathological association of CD 44v6Mrna and protein in primarg breast carcinomas.Histopathology,2003,42(6):546-554.
31.Choi YI,et al.An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions.J Histochem Cytochem 2004,52(5):591-601.
32.张向阳等.前列腺干细胞抗原在前列腺癌中表达及其临床意义,中国现代医学杂志2007,17(15):1856-1859。
33.Wente MN,et al..Prostate stem cellantigen is a putative target for immuno-therapy in pancreatic cancer.Pancreas 2005,31(2):119-125.
34.Elsamman EM,et al.prostate stem cell antigen predicts tumor recurrence in superfical transitional cell carcinoma of urinary bladder.BJU Int 2006,97(6):1202-1207.
35.Arnott D,et al.Selective detection of membrance proteins without antibodies:a mass spectrometric version of the western blot Mol cell protemics,2002,1(2):148-156.
36.Amara N,et al prostate stem cell antigen is overexpressed in human transitional cell careinoma.Cancer Res 2001,61(12):4660-4665.
37.Elsamman EM,et al.The expression of prostate stem cell antigen in human clear cell renal cell carcinoma:a quantitative reverse transcriptase-polymerase chain reaction analysis.BJU Int 2006,98(3):668-673.
38.Tai MH,et al.Oct-4 expression in adult human stem cells:evidence in support of the stem cell theory of carcinogenesis.Carcinogenesis,2005,26(2):495-502.
39.Ponti D,et al.Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.Cancer Res 2005,65(13):5506-5511.
40.Bake PM,et al.Immunohistochemi try as a tool in the differential diagnosis of ovarian tumor:an update.Int J Ggnecol Pathol 2005,24(1):39-55.
41.Choi YL,et al.Ovexexpression of CD24:association with invasiveness in urothelial carcinoma of the bladder.Arch pathol Lab Med,2007,131(3):275-281.
42.Liu R,et al.CD24 expression is a poor prognostic marker in end ometrial carcinoma.N Engl J Med,2007,356(2):217-226.
43.罗永富等,122例甲状腺癌CD44V6检测结果分析,中医药导报2007,13(1):74-75。
44.范伟等,大肠癌中Sle-x和CD44V6基因蛋白表达的研究,中国老年医学杂志,2007,27(6):466-469。
45.常瑞霞等,CD44V6在卵巢上皮性肿瘤的表达及临床意义,长治医学院学报2006,20(1):9-11.
46.贺雅莉等,宫颈癌中CD44V6的表达及其临床意义,湖北医学,2007,13(1):15-17
[2]Collins AT, Berry PS, Hyde C,etal. Prospective identification of tumorigenic prostate cancer stemcells.Cancer Res 2005,65(23):10946-10951
[3]Chang CC. Recent translational research:stem cells as the root of breast cancer. Breast Cancer Res, 2006, 8(l):103-113
[4]O'Brien CA, Pollett A, Gallinger S,etal.A human colon cancer stem cells capable of intiating tumor growth in immunodeficient mice.Nature 2007,445(7123): 106-110
[5] Ricci-vitianill,Lombard L, DG,Pilozzi E,etal.Identification and expansion of human colon-cancer-initiating cells. Nature, 2007,445(7123): 111-115.
[6]Saqiv E,Kazanov D,Arber N. CD24 plays an important role in the carcinogenesis process of pancreas. Biomed Pharmacother, 2006,60(6):280-284
[7] Li C, Heidt DG, Dalerba P, etal. Identification of pancreatic cancer stem cells. Cancer Res, 2007, 67(3): 1030-1037
[8]Prince ME, Sivanande R, Kaczorowski A,etal.Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.Pror Natl Acad Sci USA 2007,104(3):973-978
[9] Lou H, Dean M.Targeted therapy for cancer stem cells:the patched pathway and ABC transporters. Oncogene 2007,20(9):1357-1360
[10] Pellicano R,Smedile A,Saracco G,et al,Stem cells and helicobacter-induced gastric cancer:where do we stand at the end of 2006. Panminerra Med 2006,48(3): 175-179
[11] Piscaglia AC,Shupe TD,Petersen BE,etal.Stem cells,cancer,liver,and liver cancer stem cells:finding a way out of the ladyrinth...Curr Cancer Drug Targets,2007,7(6):582-590
[12]Ma S,Chan KW,Hu L,et al.Identification and characterization of turmorigenic liver cancer stem /progenitor cells.Gastroenterology,2007,132(7):2542-2556
[13]Zhiyang Z,Wenlu S.External beam radiotherapy(EBRT)suppressed prostate stem cell antigen(PSCA)mRNA expression in clinically localizd prostate cancer.Prostate 2007,67(6):653-660
[14]Grubbs EG,Abdel-wahab Z,Tyler DS,etal.Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer.Ann Surg Oncol 2006,13(12):1645-1654
[15]郎根强,孙颖浩.前列腺干细胞抗原与前列腺癌,国外医学泌尿系统分册,2002,22(5):280-282
[16]喻燕波、王共先.前列腺干细胞抗原研究进展,江西医学院学报2004,44(1):117-119
[17]张向阳,曾强,祖雄兵等.前列腺干细胞抗原在前列腺癌中的表达及其临床意义.中国现代医学杂志,2007,17(15):1856-1859
[18]Joung JY,Yang SO,Jeong IG,etal.Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer:potential value in molecular staging of prostate cancer,Int J Urol,2007,14(7):635-643
[19]Zhigang Z,Wenlu S.Prostate stem cell antigen(PSCA)mRNA expression in prostatic intraepitheliat neoplasia:implication for the development of prostate cancer,Prostate 2007,67(11):1143-1151
[20]Trosko TE.From adult stem cell to cancer stem cells:Oct-4 gene,cell-cell communication,and hormone during tumor promotion,Ann Natl Acad Sci 2006,1089(1):36-58
[21]Roman GThe role of adult stem cells in carcinogenesis.Drug New Perspect,2005,18(9):555-559
[22]Atlasi Y,Mowla SJ,Ziaee SA,etal.Oct-4,an embryonic stem cell marker,is highly expressed in bladder cancer,Int J Cancer 2007,120(7):1598-1602
[23]Kruse C,Kajahn J,Perschnik AE,et al.Adult pancreatic stem/progenitor cells spontaneously differentiate in vitro into multiple cell lineages and form teratoma like structures.Ann Anat,2006,188(6):503-517
[24]Palumba C,van Roozendaal K,Gillis AJ,etal.Expression of the PDGF alpha-receptor 1.5kb transcript,Oct-4,and C-KIT in human normal and malignant tissues.Implications for the early diagnosis of testicular germ cell tumors and for our understanding of regulatory mechanisms.J Pathol,2002,196(4):467-477
[25]严宁、张汉东、宋娟等.口腔鳞癌组织中转录因子Oct-4的表达及其与肿瘤干细胞相关性研究,临床口腔医学杂志,2006,22(11):664-666
[26]范姝君,李连宏,张众.Oct-4与生殖细胞及其肿瘤的关系,临床与实验病理学杂志,2005,21(5):609-611
[27]庄建良,苏子剑,许荣誉.CD24与肿瘤侵袭转移的关系,国际病理科学与临床杂志2006,26(5):387-390
[28]郝丽,张雁云.粘附分子CD24在肿瘤转移中的作用.细胞生物学杂志,2006,28(A):421-424
[29]庄建良,苏子剑,潘群雄等.大肠癌CD24的表达及其与肿瘤细胞增殖和血管形成的关系,世界华人消杂志,2007,15(3):260-265
[30]张永红,曾甫清.肾细胞癌中CD24蛋白的表达及其临床意义,临床泌尿外科杂志,2007,22(3):219-220
[31]Kristiansen G,Demkert C,Xchluns K.CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.Am J Pathol 2002,161(11):1215-1221
[32]Kristiansen G,Winzer KJ.CD24 expression is a new prognostic marker in breast cancer.Clin Canncer Res,2003,15(9):4906-4913
[33]Su MG,Hsu C,Kao HL,etal.CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma.Cancer Lett,2006,235(1):34-39
[34]Jacob J,Bellach J,Grutzmann R,etal.Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades.Pancreatology,2004,4(4);454-460
[35]Choi YL,Lee SH,Kwon GY,et al,Overexpression of CD24:association with invasiveness in urothelial carcinoma of the bladder.Arch Pathol Lab Med,2007,131 (3):275-281
[36]Liu R,Wang X,Chen GY?etal,CD24 expression is a poor prognostic marker in endomerrial carcinoma.N Engl J med,2007,356(2):217-226
[37]Karaha N,Gunev M,Oral B,etai,CD24 expression is a poor prognostic marker in endomerrial carcinoma.Eur J Gynaeco Oncol,2006,27(5):500-504
[38]Winkler A,Zigeuner R,Rehakp P,etal.CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumor progression.Virchews Arch,2007,450(1):59-64
[39]马丹,张珍祥,徐永健.变异型CD44分子和癌细胞的侵袭及转移.国际呼吸杂志2007,27(6):466-469
[40]罗永富,王化修,宋海鹏等.122例甲状腺癌CD44V6检测结果分析.中医药导报2007,13(1):74-75
[41]范伟,孙钦迎.大肠癌中SLe-x和CD44V6基因蛋白表达的研究,中国老年医学杂志,2007,27(6):466-469
[42]常瑞霞,肖鹏,邢燕红.CD44V6在卵巢上皮性肿瘤的表达及临床意义.长治医学院学报,2006,20(1):9-11
[43]贺雅莉,许双塔,黄旭.宫颈癌中CD44V6的表达及其临床意义.湖北医学,2007,13(1):15-17
[44]梅静,陈古福,PgP和CD44V6在胃癌中的表达及其临床意义,皖南医学院学报,2007,26(1):46-48
[45]杨艳娟,程德云,李熙霞等.骨桥蛋白OPN和粘附分子CD44V6在肺癌中表达.中国肺癌杂志,2007,10(3):189-192
[46]郑核,钟德许,苗雄鹰.CD44V5,CD44V6在胆囊癌组织中的表达研究,中国现代手术学杂志,2006,10(3):189-192
[47]Joo M,Lee Hk,Kang YK,Expression of E-cadherin,beta-catenin,CD44 and CD44V6 in gastric adenocarcinoma:relationship with lymph node metastasis.AnticancerRes,2003,23(2B):1581-1588
[48]Bendarda R,Algars A,Elzagheid A,etal.Comparison of CD44 expression in primary tumours and colorectal cancer.Oncol Rep,2006,16(4):741-746
[49]Gotodu T,Matsumura Y,Kondo H,et al.Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res 1998, 89 (10):1033-1040
[50] Berner HS, Suo Z, Risberg B,etal. Clinicopathological association of CD44V6-mRNA and protein expression in primary breast carcinomas. Histopathology 2003, 42(6):546-554
[51] Yanagis a wa N, Mikmi; T, Mitomi H,et al,CD44 variant Overexpression in gallbladder carcinoma associated with tumor dedifferentiation.Cancer 2001, 91 (2):408-416
[52]Choi YI, Xuan YH, Shin YK, etal.An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions. J Histochem Cytochem 2004, 52(5):591-601
[53] Harper LJ, Piper K, Common J,et al. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma.J Oral Pathol Med 2007,36(10):594-603
[54]Mailtland NT,Bryce SE, Stower MJ,etal.Prostate cancer stem cells:a target for new therapies.Emst Schering Found Symp Proc,2006,5(2):155-179
[55] Farnie G, Clarke RB. Breast stem cells and cancer. Ernst Schering Found Symp Proc, 2006,5(2):141-153
[56] Kakarala M, Wicha MS. Cancer stem cells: implications for cancer treatment and prevention. Cancer J, 2007,13(5):271-275
[57] Said J. Biomarker discovery in urogenital cancer. Biomarkers,2005,S-10: S83-86
[58] Wente MN, Jain A, Kono E, etal. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 2005,31 (2): 119-125
[59] Tricdi JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression;current and future diagnostic markers. Clin Cancer Res 2004, 10 (12ptl): 3943-3953.
[60] Elsamman EM, Fukumori T, Dasai T, etal, Prostate stem cell antigen predicts tumor recurrence in superfical transitional cell carcinoma of urinary bladder.BJU Int 2006, 97(6): 1202-1207
[61] Elsamman EM, Fukumor T, Tanmoto S, et al, The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantiative reverse transcriptase-polymerase chain reaction analysis.BJU Int 2006,98(3):668-673
[62] Arnott D, Kishiyama A, Luis EA, etal. Selective detection of membrance proteins without antibodies: a mass spectrometric version of the western blot. Mol Cell Protemics,2002,l(2):148-156
[63] Tai MH, Chang CC, Kiupel M, etal. Oct-4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis, 2005,26(2):495-502
[64] Altasi Y, Mewla SJ, Ziaee SA,etal. Oct-4, an embryonic stem cell marker, is highly expressed in bladder Cancer. Int J cancer 2007,120(7): 1598-1602
[65] Ponti D, Costa A, Zaffaroni N, etal. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005,65(13):5506-5511
[66] Baker PM, Oliva E. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumor: an update. Int J Gynecol Pathol 2005,24(l):39-55
[1] Dong JT, Lamb PW, Rinker-schaeffer CW, et al. KA1-1, a metastasis supressor gene for prostate cancer on human chromosome 11 pl1.2. Science 1995, 268, 52(12):884-886.
[2] Leavey PJ, Timmons C, Frawley W, et al. KA1-1 expression in pediatric high-grade osteosarcoma. Pediatr Dev Pathol, 2006,9(3):219-224.
[3] Ito Y, Uruno T, Takamura Y, et al. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology, 2005, 68(2-3):87-96.
[4] Guo XZ, Friess H, Shao X D, et al. KA1-1 gene is differently expressed in papillary and pancreatic cancer: influence on metastasis. World J Gastroenterol, 2000, 6(6).866-871.
[5]Ward M,Konishi N,Ohshima M,et al.Expression of KA1-1 in paraffin-embedded normal,hyperplastic and neoplastic prostate and prostate carcinoma cell line.Pathol Int 1998,48:87-92.
[6]Yang X,Welch DR,Phillips KK,et al.KA1-1,a putative marker for metastastic potential in human breast cancer.Cancer Lett,1997,11(s):149-155.
[7]Sun HC,Tang Z Y,Zhou G,et al.KA1-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases.J Exp Clin Cancer Res,1998,17(3):307-311.
[8]Kim JH,Kim B,Cai L,et al.Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.Nature,2005,434(7035):921-926.
[9]Martin TA,Watkins G,Jinag WG,et al.Kiss-1 expression in human breast cancer.Clin Exp Metastasis,2005,22(6):503-511.
[10]Dhar DK,Naora H,Kubota H,et al.Downregulation of Kiss-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma.Int J Cancer,2004,111(6):868-872.
[11]Ikeguchi M,Yamaguchi K,Kaibara N.Clinical significance of the loss of kiss-1 and orphan G-protenn-coupled receptor(hoT7T175) gene expression in esophageal squamous cell carcinoma.Clin Cancer Res,2004,10(4):1379-1383.
[12]Sanchez-carbayo M,Capodieci P,Cordon-cardo C.Tumor suppressor role of kiss-1 in bladder cancer:loss of kiss-1 experssion is associated with bladder cancer progression and clinical outcome.Am J Pathol,2003,162(2):609-617.
[13]张辉,赵丹懿,宋永胜.Kiss-1基因在肾癌中的表达及对细胞侵袭力的影响.中国医科大学学报,2007,36(2):171-172.
[14]梁珊,杨竹林.大鼠胰腺癌和非癌胰腺组织的Kiss-1mRNA表达。中南大学学报(医学板)2007,32(1):109-113.
[15]候元凯,王义,丛文铭等.肿瘤转移抑制基因Kiss-1和基质金属蛋白酶-9在肝细胞癌门静脉癌栓中的表达.癌症.2007,26(6):591-595.
[16]Pencil SD,Toh Y,Nicolson GL.Candiadte metastasis-assciated genes of the rat13762 NF mammary adenocarcinoma.Breast Res Treat,1993,25(2):165-174.
[17]Roepman P,deJager A,Grootkoerkamp M J,et al.Maintenance of head and neck tumor gene expression profiles upon lymph node metastasis.Cancer Res,2006,66(23):1110-1114.
[18]Balasenthil S,Broaddus RR,Kumar R.Expression of metastasis-associated protein-1(MTA1) in benign endometrium and endometrial adenocarcinomas.Hum Pathol,2006,37(6):656-661.
[19]Jang KS,Paik SS,Chung H,et al.MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancer.Cancer Sci,2006,97(5):374-379.
[20]Toh Y,Kuwano H,Mori M,et al.Overexpression of metastasis-assocated MTA1 mRANA in invasive oesophageal carcinomas.Br J Cancer,1999,79(11-12)L1723-1726.
[21]Toh Y,Oki E,Oda S,et al.Overexpression of the MTA1 gene in gastrointestinal carcinomas.correlation with invasion and metastasis.Int J Cancer,1997,74(4):459-463.
[22]Sasaki H,Moriyama S,Nakashima Y,et al.Expression of the MTAlmRNA in advanced lung cancer.Lung Cancer,2002,35(2):149-154.
[23]刘运肾,胡亚翎,刘菊梅等,肺癌PTEN,MTAl、P73表达与预后相关性.蚌埠医学院学报,2005,30(6):526-528.
[24]林川,陈汉,吴孟超等.中瘤转移基因MTAl在原发性肝癌中的表达及其临床意义.中华外科杂志,2000,38(12):915-917.
[25]Garcia S,Dales TP,Charafe-Jaccffret E,et al.Poor prognosis in breast carcinoma correlates with increased expression of targetable CD146 and C-Met and with proteomic basal-like phenotype.Hum Pathol,2007,38(6):830-841.
[26]Loges S,Clausen H,Reichelt V,et al.Determination of microvessel density by quantiative real-time PCR in esophageal cancer:correlation with histologic methods,angiogenic growth factor expression,and lymphnode metastasis.Clin Cancer Res,2007,13(1):76-80.
[27]Watson-Hurst K,Becker D.The role of N-cadherin,MCAM and beta 3integrin in melanoma progression,proliferation,migration and invasion.Cancer Biol Ther,2006,5(10):1375-1382
[28]Aldovini D,Demichelis F,Doglioni C,et al.MCAM expression as marker of prognosis in epithelial ovarian cancer.Int J Cancer,2006,119(8):1920-1926.
[29]Wu GJ,Varma VA,Wu MW,et al.Expression of a human cell adhesion molecule,MUC18,in prostate cancer cell lines and tissues.Prostate 2001,48(4):305-315.
[30]王起武,查斌,王章才.CD146及肿瘤微血管密度与前列腺癌关系的研究.皖南医院学2007,26(2):97-103.
[31]李丽萍,杨春,曹骥等.CD146mRNA在人肝细胞癌组织中的表达及其意义.现代肿瘤病学杂志,2006,14(12):1567-1570.
[32]Wright MD,Tomlinson MG.The ins and outs of the tran:membrane 4superfamily.Immunol Today,1994,15(12):588-594.
[33]Friess H,Guo XZ,Berberat P,et al.Reduced KA1-1 expression in pancreatic cancer is associated with lymph node and distant metastasis.Int J Cancer 1998,79(3):349-355.
[34]Sho M,Adachi M,Taki T,et al.Tran:membrane 4 superfamily as a progrostic factor in pancreatic cancer.Int J Cancer 1998,75(5):509-516.
[35]Dong JT,Suzuki H,Pin SD,et al.Down-regulation of the KA1-1 metastatic cancer in frequently involves gene mutation sr allelic loss.Cancer Res 1996,56(14):4387-4390.
[36]Miyazaki T,Kato H,Shitara y,et al.Mutation and expression of the metastasis suppressor squamous cell carcinoma.Cancer,2000,89:955-962.
[37]陈刚,陈森清,张晓梅等.Kai-1基因外显子缺失与大肠癌的临床关系.南京医科大学(自然科学版),2007,27(6)":594-597.
[38]孟丽辉,辛彦,吴东瑛等。胃癌组织KAl-1和nm23-H1蛋白的表达意义.世界华人消化杂志,2005,13(23):2726-2730.
[39]Lee JH,Micle ME,Hcks DJ,et al.Kiss-1,a novel human malignants melanoma metastasis-suppressor gene.Natl Cancer Inst 1996,88(23):1731-1737.
[40]Ohtaki T,Shintani Y,Honda S,et al.Metastasis suppressor gene kiss-1encodes peptide ligand of a G-protein-Cupled receptor.Nature,2001,411 (68370):613-617.
[41]Goldberg SF,Micle ME,Hata N,et al.Melanoma metastasis suppression by chromosome 6:evidence for a pathway regulated by CRSP3 and TXNIP.Cancer Res,2003,63(2):432-440.
[42]Yan C,Wang H,Beyd DD.Kiss-1 represses 92-KDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha-induced block of p65/p50 nudear transcocation.J Biol Chem,2001,276(2):1164-1172.
[43]Takino T,Koshikawa N,Miyamori H,et al.Cleavage of metastasis suppressor gene protein kiss-1 protein/metastin by matrix metalloproteniases.Oncogene,2003,22(30):4617-4626.
[44]Shirasaki F,Takao M,Hata N,et al.Loss of expression of metastasis suppressor gene kiss-1 during melanoma progression and its association with LOH of chromosome 6q~16.3-q~23.Cancer Res,2001,61(20):7422-7425.
[45]Masui T,Doi R,Mori T,et al.Metastin and its variant forms suppress migration of pancreatic cancer cells.Biochem Biophys Res Commun,2004,315(1):85-92.
[46]姚容亮,杨竹林,李永国等.转移抑制基因Kiss-1和KAl-1在胃癌组织中表达的原位杂交研究.中华胃肠外科杂志,2007,1O(3):274-277.
[47]王春晖,乔宠,戴显伟.人胰腺癌Kiss-1基因mRNA表达及其临床意义.中国肿瘤防治杂志,2006,13(3):207-210.
[48]柴丽,石林祥,房林等.Kiss-1基因及其受体在乳腺癌中的表达及临床意义.中华实验外科杂志,2005,22(9):1068-1070.
[49]Toh Y,Pencil SD,Nicloson GL.A novel candidate metastasis-assciatel gene,mtal,differentially expressed in high metastatic mammary adenocarcinoma cell lines.J Biol Chem,1994,269(37):22958-22963.
[50]Talakder AH,Mishra SK,Mandal M.MTA1 interacts with MAT1,a cyclin-depondent kinase-actuvating kinase complex ring finger factor,and regulates estrogen receptor transactivation functions.J Biol Chem,2003,178(13):11676-1685.
[51]Iguchi H,Imura G,Toh Y,et al.Expression of mtal,a metastasis-associated gene with histone deacetyase activity in pancreatic cancer.Int J Oncol,2002,16
[52]唐正严,祖雄兵,齐琳等.膀胱移行细胞癌Mta-1基因与蛋白表达及其临床意义.临床泌尿外科杂志,2006,21(8):595-597.
[53]李丽萍,曹骥,杨春.CD146与肿瘤的关系.中华肿瘤防治杂志,2007,14(8):635-637.
[54]Bittner M,Meltzer P,Chen Y,et al.Molecular classification of cutaneous malignant melanoma by gene expression profiling.Nature,2000,406(6795):536-540.
[55]Kristiansen G,Yu Y,Schluns K,et al.Expression of the cell adhesion moleule CD146/MCAM in non-small cell lung cancer,Anal Cell Pathol,2003,25(2):77-81.
[56]Shih IM,Hsu MY,Palazzo J P,et al.The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma.Am J Pathol,1997,151(3):745-751.
1.Anton Aparicio LM,et al.Prostate careinoma and stem cells.Clin Transl Oncol 2007,9(2):66-76.
2.Collins AT,et al.Prospective identification of tunnorigenic prostate cancer stem cells.Cancer Res 2005,65(23):1049-1095.
3.ChanCC.Recent translational research:stem cells a the root of breast cancer.Breast cancer Res,2006,8(1):103-113.
4.O'Brien CA,et al.A human colon cancer stem cells capable of intitating tumor growth in immunodeficient mice.Nature 2007,445(7123):106-110.
5.Saqiv E,etal.CD24 plays an important role in the carcinogenesis process of parcreas.Biomed pharaamother 2006,60(6):280-284.
6.Li C,et al Identification of pancreatic cancer stem cells.Cancer Res 2007,67(3):1030-1037.
7.Prince ME,et al.Identification of a subopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.Proic Natl Acod Sci VSA2007,104(3):973-978.
8.Lou H,et al.Targeted therapy for cancer stem cells:the patched pathway and ABC transporters.Qncogene 2007,20(9):1357-1360.
9.Pellican R,et al stem cells and helicobacter-induced gastric calleer.Where do we stand at the end of 2006.Panminerra Med 2006,48(3):175-179.
10.Piscaglia AC,et al.stem cells,cancer,liver,and liver cancer stem cells:finding a way out of the Ladyrinth…….Curr cancer Drug Targets 2007,7(6)582-596.
11.Ma S et al.Identification and characterization of tumerigenic liver cancer stem/progenitor cells.Gastroenterology 2007,132(7):2542-2556.Kong DS,et al.The progression of gliomas is associated with cancer stem cell phenotype.Oncol Rep 2008,19(3):639-643.
12.喻燕波等,前列腺于细胞抗原研究进展,江西医学院学报2004,44(1):117-119.
13.朗根强等,前裂腺干细胞抗原与前列腺癌,国外医学泌尿系统分册,2002,22(5):280-282.
14.Zhiyang z,et al.Prostate stem cell antigen(PSCA)mRNA expression in prostatic intraepithelial neoploasia:implication for the development of prostate cancer.Prostate 2007,67(11):1143-1151.
15.young JY,et al.Reverse transcriptase-polymerase chain lieaction and immuno-histochemical studies for deteertion of prostate stem cell antigen expression in prostate cancer:potential value in molecular staging of prostate cancer.Int J Urol 2007,14(7):635-643.
16.Grubb EG,et al.Vtilizing quantitative polgmerase chain reaction to eraluate prostate stem cell antigen as a tumor marher in pancreatic cancer:Ann Surg Oncol 206,13(12):1645-1654.
17.Trosko TE,et al.From adult stem cell to cancer stem cells.Oct-4 gene,cell-cell communication,and hormone during tumor promotion.Ann Natl Acad Sci 2006,1089(1):36-58.
18.Roman G The role of adut stem cells in carcinogenesis.Drug New perspect 2005,18(9):555-559.
19.Atlasi Y,et al.Oct-4,an embryonic stem cell marker,is highly expressed in bladder cancer.Int J Cancer 2007,120(7):1598-1602.
20.严宁等,口腔鳞癌组织中转录因子Oct-4的表达及其与肿瘤干细胞相关性研究,临床口腔医学杂志,2006,22(11):664-666.
21.范姝君等,Oct-4与生殖细胞及其肿瘤的关系,临床实验病理学杂志,2005,21(5):609-611.
22.庄建良,等.CD24与肿瘤侵袭转移的关系,国际病理科学与临床杂志,2006,26(5):387-390
23.郝丽等,粘附分子CD24在肿瘤转移中的作用,细胞生物学杂志,2006,28(A):421-424。
24.Kristiansen G,et al.CD24 is expressed in ovarian Cancer and is a new independent grognostic marker of patient survival.Am J pathrel 2002,161(1):1215-1221.
25.Kristiansen G,et al CD24 expression is a new prognostic morker in breast cancer.Clin cancer Res.2003,15(9):4906-4913.
26.Jacob J,et al.Expression of CD24 in adenocarcinomas of the pancreas correlates with higher rumor grades.Pancreatology 2004,4(4):454-460.
27.马丹等,变异型CD44分子和癌细胞的侵袭及转移,国际呼吸杂志2007,27(6):466-469.
28.JooM,et al Expression of E-cadherin,beta-catenin,CD44 and CD44V6 in gastric adeno-carcinoma:relationship with lymphnode metastasis.Anticancer Res 2003,23(2B):1581-1588.
29.Bendarda R,etal comparision of CD44 expression in primary tumors and coloretal cancer.oncd Rep,2006,16(4):741-146.
30.Berner Hs,etal clinicopathological association of CD 44v6Mrna and protein in primarg breast carcinomas.Histopathology,2003,42(6):546-554.
31.Choi YI,et al.An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions.J Histochem Cytochem 2004,52(5):591-601.
32.张向阳等.前列腺干细胞抗原在前列腺癌中表达及其临床意义,中国现代医学杂志2007,17(15):1856-1859。
33.Wente MN,et al..Prostate stem cellantigen is a putative target for immuno-therapy in pancreatic cancer.Pancreas 2005,31(2):119-125.
34.Elsamman EM,et al.prostate stem cell antigen predicts tumor recurrence in superfical transitional cell carcinoma of urinary bladder.BJU Int 2006,97(6):1202-1207.
35.Arnott D,et al.Selective detection of membrance proteins without antibodies:a mass spectrometric version of the western blot Mol cell protemics,2002,1(2):148-156.
36.Amara N,et al prostate stem cell antigen is overexpressed in human transitional cell careinoma.Cancer Res 2001,61(12):4660-4665.
37.Elsamman EM,et al.The expression of prostate stem cell antigen in human clear cell renal cell carcinoma:a quantitative reverse transcriptase-polymerase chain reaction analysis.BJU Int 2006,98(3):668-673.
38.Tai MH,et al.Oct-4 expression in adult human stem cells:evidence in support of the stem cell theory of carcinogenesis.Carcinogenesis,2005,26(2):495-502.
39.Ponti D,et al.Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.Cancer Res 2005,65(13):5506-5511.
40.Bake PM,et al.Immunohistochemi try as a tool in the differential diagnosis of ovarian tumor:an update.Int J Ggnecol Pathol 2005,24(1):39-55.
41.Choi YL,et al.Ovexexpression of CD24:association with invasiveness in urothelial carcinoma of the bladder.Arch pathol Lab Med,2007,131(3):275-281.
42.Liu R,et al.CD24 expression is a poor prognostic marker in end ometrial carcinoma.N Engl J Med,2007,356(2):217-226.
43.罗永富等,122例甲状腺癌CD44V6检测结果分析,中医药导报2007,13(1):74-75。
44.范伟等,大肠癌中Sle-x和CD44V6基因蛋白表达的研究,中国老年医学杂志,2007,27(6):466-469。
45.常瑞霞等,CD44V6在卵巢上皮性肿瘤的表达及临床意义,长治医学院学报2006,20(1):9-11.
46.贺雅莉等,宫颈癌中CD44V6的表达及其临床意义,湖北医学,2007,13(1):15-17
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |